Published by Coherent Market Insights
Posted on September 20, 2021
4 min readLast updated: February 5, 2026
The cancer biomarkers market is set to grow at a 14.2% CAGR from 2021-2027, driven by advancements in cancer diagnosis and research collaborations.
Coherent Market Insights released a new market study on 2021-2027 Cancer Biomarkers Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 Cancer Biomarkers Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/175
Cancer biomarkers are tools used to detect the disease process and monitor the response to therapy in cancer patients. A cancer biomarker refers to any substance or procedure that is characteristic of the existence of cancer in the human body. A biomarker can be a substance secreted by the tumor itself or a general biological response of the human body to the existence of cancer. These substances include serum creatinine, tumor antigens, cytokines, free radicals, chemo markers, DNA methylation, and receptor antigens.
Many cancer biomarkers currently being tested in clinical trials to assess their activity on various cancers. Although these tests are still at an early stage, many exciting results are being seen with each passing day. Moreover, continued advances in cancer diagnosis include the use of molecular biomarkers as part of routine clinical trials. Molecular alterations used for cancer diagnosis involves application of DNA, RNA, microRNAs, and proteins.
Market Dynamics:
Increasing incidence/prevalence of cancer worldwide is expected to fuel the growth of the cancer biomarkers market. For instance, according to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018.
Moreover, continuous advancements in cancer diagnosis are also expected to augment the growth of the cancer biomarkers market. For instance, in January 2021, biomedical engineers at Duke University devised an algorithm to find new biomarkers and better understand how numerous cancers affect the human body.
Increasing number of collaborations and partnerships and increasing research and development activities are expected to propel the growth of the cancer biomarkers market. For instance, in January 2021, Indian Institute of Technology (Guwahati) signed MoU with North East Cancer Hospital and Research Institute (NECHRI), Assam (India) to identify novel biomarkers for cancer diagnosis, prognosis, therapy, and recurrence.
Increasing use of cancer biomarkers in drug discovery and development and increasing research on cancer biomarkers is also expected to aid the market growth.
North America is expected to witness substantial growth in the cancer biomarkers market due to increasing prevalence of cancer in the region. For instance, according to American Cancer Society, there were likely to be approximately 1,806,590 new cancer cases and 606,520 deaths in the United States in 2020.
Cancer Biomarkers Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/175
Reasons to Purchase this Report
• Current and future of global Cancer Biomarkers Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Cancer Biomarkers Market Research Study are:
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/175
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer biomarkers market is expected to witness a CAGR of 14.2% over the forecast period (2021–2027). Major Players Are BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories appeared first on Gatorledger.
The article discusses the growth and dynamics of the cancer biomarkers market from 2021 to 2027.
Major players include BioMerieux S.A., Bard1 Life Sciences Limited, and Bio-Rad Laboratories.
Market growth is driven by advancements in cancer diagnosis and increased research and development.
Explore more articles in the Research Reports category
